In the ongoing SURPASS-CVOT (comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease), 13,299 diabetic subjects with established atherosclerotic CVD were randomized to receive tirzepatide, a once-weekly GIP/GLP-1 receptor agonist, and dulaglutide, a GLP1-RA, to investigate cardiovascular safety and efficacy [119]. The gene discussed is GIP; the disease is type 2 diabetes mellitus.